Rapamycin alleviates mitochondrial dysfunction in anti-NMDAR encephalitis mice

Liangbo Kong1, Xiaxin Yang1, Anqi Sun1

  • 1Department of Neurology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Ji'nan, Shandong, China.

PubMed

Insights

Mitochondrial dysfunction, marked by excessive fission and impaired autophagy, drives anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Rapamycin treatment reversed these changes, improving cognitive and behavioral deficits in mice.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a common autoimmune disorder causing neurological and psychiatric symptoms.
  • The precise pathological mechanisms underlying anti-NMDAR encephalitis are not fully understood.

Purpose of the Study:

  • To investigate the role of mitochondrial dysfunction in anti-NMDAR encephalitis.
  • To explore the therapeutic potential of targeting the mTOR signaling pathway with rapamycin.

Main Methods:

  • Active immunization in a mouse model of anti-NMDAR encephalitis.
  • Assessment of mitochondrial fission, autophagic flux, mitochondrial reactive oxygen species (mtROS), and mitochondrial DNA (mtDNA).
  • Evaluation of the mechanistic target of rapamycin (mTOR) signaling pathway and the effects of rapamycin treatment.

Main Results:

  • Mice with anti-NMDAR encephalitis exhibited increased mitochondrial fission and blocked autophagic flux, leading to elevated mtROS and mtDNA.
  • Overactivation of the mTOR pathway exacerbated mitochondrial dysfunction.
  • Rapamycin treatment inhibited mitochondrial fission, enhanced autophagy, reduced mtROS and mtDNA, and improved cognitive and behavioral impairments.

Conclusions:

  • Mitochondrial dysfunction is a key pathological factor in anti-NMDAR encephalitis.
  • Targeting the mTOR pathway with rapamycin shows therapeutic promise for anti-NMDAR encephalitis.

Related Concept Videos